Free tool
FAERS Monitor: Supprelin La
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022058 or its brand name (Supprelin La, Histrelin Acetate). Reports on generic versions are filed under their own applications.
Reports
877
Serious
186
21% of reports
Hospitalization
48
Death reported
28
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective138
- device breakage117
- procedural complication83
- incorrect drug administration duration65
- incorrect product administration duration60
- rash46
- implant site rash41
- headache39
- off label use34
- weight increased31
- mood swings28
- device expulsion27
- implant site pain27
- implant site infection23
- rash pruritic23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 7 |
| 2011 | 10 |
| 2012 | 11 |
| 2013 | 220 |
| 2014 | 60 |
| 2015 | 112 |
| 2016 | 71 |
| 2017 | 70 |
| 2018 | 45 |
| 2019 | 42 |
| 2020 | 39 |
| 2021 | 24 |
| 2022 | 42 |
| 2023 | 31 |
| 2024 | 45 |
| 2025 | 24 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,282 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| implant site rashSignal | 41 | 3104.9 | 2258.0 | 109,919 |
| procedural complicationSignal | 83 | 262.4 | 213.6 | 21,134 |
| implant site infectionSignal | 23 | 239.5 | 159.7 | 5,176 |
| implant site painSignal | 27 | 145.8 | 100.4 | 3,717 |
| device breakageSignal | 117 | 69.3 | 58.5 | 7,803 |
| incorrect product administration durationSignal | 60 | 66.6 | 52.2 | 3,805 |
| incorrect drug administration durationSignal | 65 | 55.5 | 43.9 | 3,424 |
| mood swingsSignal | 28 | 21.1 | 14.6 | 516 |
| rash pruriticSignal | 23 | 10.2 | 6.8 | 182 |
| device expulsionSignal | 27 | 10.0 | 6.9 | 210 |
| weight increasedSignal | 31 | 3.3 | 2.3 | 48 |
| rashSignal | 46 | 2.5 | 1.9 | 42 |
| drug ineffectiveSignal | 138 | 2.5 | 2.2 | 132 |
| headache | 39 | 1.5 | 1.1 | 6 |
| off label use | 34 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.